Boulevard Bio Emerges from Stealth with $65 Million Funding Led by Deerfield Management

Boulevard Bio Secures $65 Million in New Funding

Boulevard Bio, a New York-based biotech firm, has announced a $65 million funding round led by Deerfield Management. The company specializes in developing multi-specific antibodies aimed at treating B cell-driven autoimmune diseases using precision immunology.

Company Overview

Founded by Frank Nestle and helmed by CEO Mahesh Karande, Boulevard Bio is focused on advancing its pipeline of therapeutic candidates. The company has been incubated by Deerfield Management's Discovery and Development (3DC) team, which is dedicated to pioneering innovative therapies.

Lead Investor: Deerfield Management

The funding round was spearheaded by Deerfield Management, a prominent investor in the healthcare sector. This financial backing will enable Boulevard Bio to further its research and development efforts.

Use of Funds

The newly secured funds will be directed towards advancing Boulevard Bio's lead candidate, BLVD101. This candidate is a dual BAFF/APRIL-targeting bispecific antibody designed for the treatment of IgA nephropathy (IgAN), a kidney disease. Early Phase 1 trials with healthy volunteers have shown promising data, indicating a 12-week dosing interval for the treatment.

Looking Ahead

With this significant investment, Boulevard Bio aims to continue optimizing its pipeline, focusing on therapeutic solutions that improve the quality of life for individuals affected by chronic autoimmune diseases.